Adaptimmune Annual report pursuant to Section 13 and 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 10,414	$ 11,053	$ 16,202
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	4,417	3,812	8,340
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 5,997	$ 7,241	$ 7,862